Processa Acquires Vidya Therapeutics in Reverse Merger, Raises $200M PIPE to Advance BTK Inhibitor
PCSA sits 55% above its 52-week low of $1.67 on elevated volume (2.1× avg).
Summary
Processa Pharmaceuticals completed a reverse merger with Vidya Therapeutics and a concurrent $200 million PIPE, gaining a BTK inhibitor pipeline and funding through 2029. Existing Processa shareholders were diluted to less than 1% ownership.
Key Events · M&A and Partnerships · PCSA
-
Reverse Merger with Vidya Therapeutics
Processa acquired Vidya in a stock-for-stock transaction, issuing 558,398 common shares and 142,744.100 Series A preferred shares (convertible into 142.7M common shares) to Vidya stockholders. Vidya became a wholly owned subsidiary.
-
$200 Million PIPE Financing
Concurrent private placement of 163,774.679 Series A preferred shares at $1,221.19 per share (equivalent to $1.22119 per common share on an as-converted basis) raised approximately $200 million from a syndicate of leading healthcare investors.
-
Massive Ownership Dilution
Post-transaction, pre-existing Processa stockholders own only ~0.9% of the combined company on a fully-diluted basis, while Vidya equityholders hold ~46% and PIPE investors ~52.6%.
-
Pipeline Transformation to BTK Inhibitor VT-7208
The combined company's lead asset is VT-7208, a CNS-penetrant BTK inhibitor with Phase 1 data completed. Phase 2 proof-of-concept studies in food allergy, CSU, and RMS are planned, with data readouts expected in 2027-2028.
Analysis · PCSA · Life Sciences
Processa Pharmaceuticals has been acquired by Vidya Therapeutics through a reverse merger, transforming the company's pipeline and ownership. The combined entity gains VT-7208, a clinical-stage BTK inhibitor, and $200 million in concurrent PIPE financing from top-tier healthcare investors. Pre-transaction Processa stockholders are diluted to approximately 0.9% ownership, while Vidya equityholders hold ~46% and PIPE investors ~52.6%. The capital extends cash runway into H2 2029, funding Phase 2 studies in food allergy, CSU, and RMS. This is a thesis-altering event: the legacy Processa pipeline is deprioritized, the management team remains but the board gains Vidya's founder, and the company's market cap and strategic direction are entirely reset.
At the time of this filing, PCSA was trading at $2.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.4M. The 52-week trading range was $1.67 to $14.24. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.